This study investigated the effect of 8 weeks of treatment with ramipril or losartan on N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels, plasminogen activator inhibitor-1 (PAI-1) activity, echocardiographic parameters and lipid profiles in patients after acute myocardial infarction (MI). Patients were randomly assigned to receive up to 10 mg/day ramipril (n = 27) or up to 100 mg/day losartan (n = 26). No significant differences in any of the tested variables were observed between the two treatment groups, either before or after treatment. Within the losartan-treated group a significant decrease in levels of NT-proBNP (211.1 ± 211.5 versus 94.7 ± 150.1 pg/ml), total cholesterol (5.7 ± 1.0 versus 4.6 ± 1.1 mmol/l), and low-density lipoprotein-cholesterol (3.5 ± 0.9 versus 2.7 ± 1.0 mmol/l) was observed after treatment compared with baseline. Thus, after an acute MI, losartan seems equal to ramipril in terms of the NT-proBNP levels, echocardiographic parameters, PAI-1 activity and lipid profiles that were achieved.
ACE Inhibitor Myocardial Infarction Collaborative Group: Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100 000 patients in randomized trials. Circulation1998; 97: 2202–2212.
2.
VaughanDERouleauJ-LRidkerPM: Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation1997; 96: 442–447.
3.
López-SendónJSwedbergKMcMurrayJ: Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J2004; 25: 1454–1470.
4.
BomanKOJanssonJ-HNyhlénKA: Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction. Thromb Haemost2002; 87: 311–316.
5.
ShahADAroraRR: Tissue angiotensin-converting enzyme inhibitors: Are they more effective than serum angiotensin-converting enzyme inhibitors?Clin Cardiol2005; 28: 551–555.
6.
YusufSSleightPPogueJ: Effect of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation Study Investigators. N Engl J Med2000; 342: 145–153.
7.
FoxKM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA Study). Lancet2003; 362: 782–788.
8.
DicksteinKKjekshusJ: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Lancet2002; 360: 752–760.
9.
OgiharaTYoshinagaK: The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension. Blood Press Suppl1996; 2: 78–81.
10.
LerchMTeuscherAUBeissnerP: Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. J Cardiovasc Pharmacol1998; 31: 576–580.
11.
HanefeldMAbletshauserC: Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res2001; 29: 270–279.
12.
StraussMHHallAS: Angiotensin receptor blockers may increase risk of myocardial infarction: Unraveling the ARB–MI paradox. Circulation2006; 114: 838–854.
13.
McDonaldMASimpsonSHEzekowitzJA: Angiotensin receptor blockers and risk of myocardial infarction: Systematic review. BMJ2005; 331: 873.
14.
MairJFriedlWThomasS: Natriuretic peptides in assessment of left ventricular dysfunction. Scand J Clin Lab Invest1999; 59: 132–142.
15.
BettencourtPFerreiraAOliveiraN Pardal: Clinical significance of brain natriuretic peptide in patients with postmyocardial infarction. Clin Cardiol2000; 23: 921–927.
16.
De LemosJAMorrowDABentleyJH: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med2001; 345: 1014–1021.
17.
TroughtonRWFramptonCMYandleTG: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet2000; 355: 1126–1130.
18.
NordtTKPeterKRuefJ: Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost1999; 82 (suppl 1): 14–18.
19.
VaughanDE: PAI-1 and atherothrombosis. J Thromb Haemost2005; 3: 1879–1883.
20.
AgirbasliM: Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract2005; 59: 102–106.
21.
TrostSPratleyRSobelB: Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Curr Diab Rep2006; 6: 47–54.
22.
SmithAPattersonCYarnellJ: Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation2005; 112: 3080–3087.
23.
SinkovicAPogacarV: Risk stratification in patients with unstable angina and/or non-ST-elevation myocardial infarction by troponin T and plasminogen-activator-inhibitor-1 (PAI-1). Thromb Res2004; 114: 251–257.
24.
SinkovičA: Plasminogen-activator-inhibitor-1 in patients with atrial arrhythmias during acute myocardial infarction, treated with streptokinase. Blood Coagul Fibrinolysis2002; 13: 741–747.
25.
Van de WerfFArdissinoDBetriuA: Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J2003; 24: 28–66.
26.
OttoCM: Left and right ventricular systolic function. In: Textbook of Clinical Echocardiography (OttoCM, ed). Philadelphia: Elsevier Saunders, 2004; pp 140–141.
27.
KillipTKimballJT: Treatment of myocardial infarction in a coronary care unit. A two years experience with 250 patients. Am J Cardiol1967; 20: 457–464.
28.
OmlandTPerssonANgL: N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation2002; 106: 2913–2918.
29.
ErdemYUsalanCHaznedaroğluIC: Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens1999; 12 (11 pt 1): 1071–1076.
30.
WienbergenHSchieleRGittAK: Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. Am J Cardiol2002; 90: 1045–1049.
31.
SquireIBØrnSNgLL: Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to prognosis: An OPTIMAAL substudy. J Cardiac Fail2005; 11: 492–497.
32.
JaraiRWojtaJHuberK: Circulating B-type natriuretic peptides in patients with acute coronary syndromes. Pathophysiological, prognostic and therapeutical considerations. Thromb Haemost2005; 94: 926–932.
33.
WasedaKOzakiYTakashimaH: Impact of angiotensin II receptor blockers on the progression and regression of coronary atherosclerosis: An intravascular ultrasound study. Circ J2006; 70: 1111–1115.
34.
KohKKSonJWAhnJY: Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension2004; 44: 180–185.
35.
MorawietzHErbsSHoltzJ: Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: The EPAS trial. Circulation2006; 114 (suppl 1): I296–I301.
36.
KvanEReikvamA: The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: Results from a study of patients discharged from hospital after an acute myocardial infarction. Eur J Clin Pharmacol2004; 60: 205–210.
37.
TsutamotoTWadaAMaedaK: Plasma brain natriuretic peptide as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimal symptomatic left ventricular dysfunction. Eur Heart J1999; 20: 1799–1807.
38.
AkashiYJSpringerJLainscakM: Atrial natriuretic peptide and related peptides. Clin Chem Lab Med2007; 45: 1259–1267.
